Premium
ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP FOR PATIENTS ≤65Y WITH UNTREATED NON‐GERMINAL CENTER B‐CELL–LIKE DIFFUSE LARGE B‐CELL LYMPHOMA
Author(s) -
Sehn L. H.,
Kahl B.,
Matasar M.,
Lentz G.,
Izutsu K.,
Zhao W.,
Tao L.,
Calvo R.,
Zinzani P. L.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.164_2880
Subject(s) - diffuse large b cell lymphoma , medicine , population , chop , vincristine , rituximab , ibrutinib , oncology , gastroenterology , lymphoma , cyclophosphamide , chronic lymphocytic leukemia , chemotherapy , leukemia , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom